Balsm Alofoq Medical Company (TADAWUL:9620)

TADAWUL:9620 Balance Sheet

Financials in millions SAR. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	18.24	3.68	5.74
Cash & Short-Term Investments	18.24	3.68	5.74
Cash Growth	396.05%	-35.90%	-
Accounts Receivable	0.34	0.3	0.3
Other Receivables	0.28	0.04	0.02
Receivables	0.62	0.34	0.32
Inventory	1.72	1.5	0.68
Prepaid Expenses	0.03	-	-
Other Current Assets	0.59	0.28	0.66
Total Current Assets	21.2	5.8	7.39
Property, Plant & Equipment	12.08	12.86	7.51
Total Assets	33.28	18.66	14.9
Accounts Payable	0.27	0.34	0.44
Accrued Expenses	0.79	0.84	0.62
Current Portion of Leases	0.31	0.23	0.5
Current Income Taxes Payable	0.26	0.1	0.12
Other Current Liabilities	-	0.01	2.69
Total Current Liabilities	1.64	1.52	4.37
Long-Term Leases	1.5	1.69	2.13
Total Liabilities	4.36	4.27	7.54
Common Stock	12.5	10	4.9
Additional Paid-In Capital	10.15	-	-
Retained Earnings	6.27	4.39	2.46
Shareholders' Equity	28.92	14.39	7.36
Total Liabilities & Equity	33.28	18.66	14.9
Total Debt	1.8	1.93	2.62
Net Cash (Debt)	16.44	1.75	3.11
Net Cash Growth	838.03%	-43.71%	-
Net Cash Per Share	16.10	2.38	-
Filing Date Shares Outstanding	1.25	0.74	-
Total Common Shares Outstanding	1.25	0.74	-
Working Capital	19.56	4.28	3.02
Book Value Per Share	23.13	19.43	-
Tangible Book Value	28.92	14.39	7.36
Tangible Book Value Per Share	23.13	19.43	-
Land	5.13	5.13	-
Buildings	3.36	3.36	-
Machinery	6.46	6.27	6.17
Leasehold Improvements	1.13	1.11	2.55

Source: S&P Global Market Intelligence. Standard template. Financial Sources.